Compare 8x8 Inc (EGHT) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
8x8 Inc vs Merck & Co., Inc. — how do they compare? 8x8 Inc trades at $2.11 (market cap $311.98M), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 1126× 8x8 Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while 8x8 Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold 8x8 Inc for 16 Days and Merck & Co., Inc. for 98 Days on average.
| EGHT | MRK | |
|---|---|---|
Market Cap | $311.98M | $351.28B |
Volume | 1,639,086 | 7,969,665 |
Sector | Technology | Health |
52-Week High | $2.76 | $156.43 |
52-Week Low | $1.59 | $82.49 |
Typical Hold Time | 16 Days | 98 Days |
Enterprise Value | $578.90M | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EGHT trades at $2.13, down 0.47% on the day, with a bullish technical signal supported by moving averages. The company shows strong revenue growth with $715M in 2025 and positive earnings beats in recent quarters, though profitability remains challenged with a net loss of $27M. Recent news highlights cost-saving customer implementations and AI platform growth, while analyst consensus is mixed with a $19.77 price target representing significant upside potential.
EGHT presents a high-risk, high-reward opportunity with substantial analyst upside but faces execution risks amid competitive pressures. The stock's current valuation at 72x P/E reflects growth expectations, but investors must weigh the company's debt load and margin challenges against its strategic positioning in cloud communications and AI innovation.
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal and key support at $140. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.14. Revenue grew to $65.01B in 2025, and net income reached $18.25B, though the P/E ratio is elevated at 113.9. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook for MRK is mixed, with solid fundamentals and analyst optimism countered by high valuation and bearish technicals. The consensus price target of $158.78 suggests upside potential, but investors face risks from competitive pressures and integration challenges from recent M&A activity. Earnings growth and pipeline developments remain key catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
